MTX-101 (Mozart Therapeutics Inc.) is a bispecific CD8 Treg modulator that targets CD8 and the KIR2DL family, including KIR2DL1, KIR2DL2 and KIR2DL3, and is being developed for the treatment of CD4-driven autoimmunity and restoring immune balance.
Mozart Therapeutics Inc. has reported preclinical pharmacologic and tolerability data for MTX-101, a bispecific CD8 regulatory T-cell (Treg) modulator targeting inhibitory KIR2DL(1/2/3) and CD8 expressed on CD8 Tregs. The autoimmune checkpoint inhibitor aims to restore CD8 Treg function, acting early in the autoimmune disease process to halt downstream inflammation and prevent further complication. The initial therapeutic focus for MTX-101 is gastrointestinal autoimmune disorders.
